文献速递呼吸道感染呼吸危重症与机械通气

COVID-19重症患者ARDS表型患病率的前瞻性观察研究

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.
PubMed 文献 · Lancet Respir Med · 2020-08-27

该前瞻性观察研究在英国两个ICU纳入39例COVID-19相关ARDS患者,用IL-6、可溶性TNFR1和碳酸氢盐计算高炎症表型概率。高炎症表型患病率为10%-21%,低于历史HARP-2队列的35%,COVID-19相关ARDS未显示更高全身炎症。

要点

  • COVID-19相关ARDS高炎症表型患病率低于非COVID-19 ARDS历史数据。
  • COVID-19相关ARDS患者可溶性TNFR1水平显著低于匹配的HARP-2患者。
  • 该队列28天病死率44%,高炎症表型分类下病死率无显著差异。

核心结论

  • COVID-19相关ARDS与更高全身炎症无关,高炎症表型患病率低于历史ARDS数据。
  • COVID-19相关ARDS的超额死亡不太可能由简约模型描述的上调炎症通路所致。

研究设计与样本

  • 前瞻性观察研究,在英国两个重症监护病房招募39例COVID-19相关ARDS患者。
  • 基线收集人口学、临床和实验室数据,用即时检测分析血浆IL-6和可溶性TNFR1。
  • 用简约回归分类器模型基于IL-6、可溶性TNFR1和碳酸氢盐计算高炎症表型概率。
  • 数据与既往英国多中心辛伐他汀随机对照试验(HARP-2)中非COVID-19 ARDS患者比较。

主要发现

  • 39例患者中位PaO2/FiO2为18 kPa(IQR 15-21),APACHE II评分为12(10-16)。
  • 39例患者中17例(44%)在28天时死亡。
  • 高炎症表型患病率为39例中4例(10%)至8例(21%),低于HARP-2的539例中186例(35%)。

关键数值与推荐

  • HARP-2队列高炎症表型比例为186/539(35%)。

临床怎么用

  • 对COVID-19相关ARDS患者,不应常规假定存在高炎症表型而据此选择抗炎治疗。
  • IL-6和可溶性TNFR1联合碳酸氢盐的简约模型可用于表型概率评估,但需进一步验证。

局限性

  • 探索性分析样本量小(39例),来自两个ICU,结果需谨慎解读。
  • 历史对照来自不同时期和试验队列,可能存在人群和治疗差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In acute respiratory distress syndrome (ARDS) unrelated to COVID-19, two phenotypes, based on the severity of systemic inflammation (hyperinflammatory and hypoinflammatory), have been described. The hyperinflammatory phenotype is known to be associated with increased multiorgan failure and mortality. In this study, we aimed to identify these phenotypes in COVID-19-related ARDS. METHODS: In this prospective observational study done at two UK intensive care units, we recruited patients with ARDS due to COVID-19. Demographic, clinical, and laboratory data were collected at baseline. Plasma samples were analysed for interleukin-6 (IL-6) and soluble tumour necrosis factor receptor superfamily member 1A (TNFR1) using a novel point-of-care assay. A parsimonious regression classifier model was used to calculate the probability for the hyperinflammatory phenotype in COVID-19 using IL-6, soluble TNFR1, and bicarbonate levels. Data from this cohort was compared with patients with ARDS due to causes other than COVID-19 recruited to a previous UK multicentre, randomised controlled trial of simvastatin (HARP-2). FINDINGS: Between March 17 and April 25, 2020, 39 patients were recruited to the study. Median ratio of partial pressure of arterial oxygen to fractional concentration of oxygen in inspired air (PaO2/FiO2) was 18 kpa (IQR 15-21) and acute physiology and chronic health evaluation II score was 12 (10-16). 17 (44%) of 39 patients had died by day 28 of the study. Compared with survivors, patients who died were older and had lower PaO2/FiO2. The median probability for the hyperinflammatory phenotype was 0·03 (IQR 0·01-0·2). Depending on the probability cutoff used to assign class, the prevalence of the hyperinflammatory phenotype was between four (10%) and eight (21%) of 39, which is lower than the proportion of patients with the hyperinflammatory phenotype in HARP-2 (186 [35%] of 539). Using the Youden index cutoff (0·274) to classify phenotype, five (63%) of eight patients with the hyperinflammatory phenotype and 12 (39%) of 31 with the hypoinflammatory phenotype died. Compared with matched patients recruited to HARP-2, levels of IL-6 were similar in our cohort, whereas soluble TNFR1 was significantly lower in patients with COVID-19-associated ARDS. INTERPRETATION: In this exploratory analysis of 39 patients, ARDS due to COVID-19 was not associated with higher systemic inflammation and was associated with a lower prevalence of the hyperinflammatory phenotype than that observed in historical ARDS data. This finding suggests that the excess mortality observed in COVID-19-related ARDS is unlikely to be due to the upregulation of inflammatory pathways described by the parsimonious model. FUNDING: US National Institutes of Health, Innovate UK, and Randox.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020. PMID: 32861275. doi:10.1016/S2213-2600(20)30366-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。